Skip to content
Peptide research

Pal-AHK

Also known as Palmitoyl-Ala-His-Lys
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

What it is

A palmitoylated tripeptide marketed in cosmetic serums for skin collagen stimulation and hair growth. The case rests almost entirely on cell-culture and mechanism studies in fibroblasts and dermal papilla cells, with no meaningful human data. There is essentially no human safety data, so its long-term profile is unknown. It is not an FDA-approved drug, sold as a cosmetic ingredient or unregulated research-grade product, with no role in clinical practice.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Stimulation of collagen type I synthesis in fibroblasts

    Speculative

    Collagen stimulation is documented for the related peptide GHK-Cu, not directly tested for Pal-AHK.

  • Hair follicle elongation and dermal papilla cell proliferation

    Speculative

    Single in vitro study using AHK-Cu (not Pal-AHK) in human follicle organ culture.

  • Anti-apoptotic activity in dermal papilla cells

    Speculative

    One cell-culture study; the main apoptosis assay (flow cytometry) was not statistically significant.

Evidence limits

Evidence Level
Preclinical

All evidence for Pal-AHK derives from in vitro cell culture studies on the parent AHK tripeptide and its copper complex AHK-Cu. The key mechanistic study is Pyo et al. 2007 on AHK-Cu and hair follicle growth, conducted at Seoul National University using ex vivo human hair follicles and cultured dermal papilla cells. No randomized controlled trials, no prospective cohort studies, and no clinical efficacy trials have been conducted with Pal-AHK in human subjects. The cited CIR assessment does not evaluate Pal-AHK. The clinical evidence gap is significant — most marketing claims for Pal-AHK are extrapolated from in vitro data or from studies on related but distinct palmitoyl peptides (Pal-GHK, pal-KTTKS).

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • No human clinical efficacy data

    High
  • Local skin irritation and sensitization

    Low
  • Copper toxicity risk when combined with copper supplements or AHK-Cu

    Theoretical
  • Formulation instability with certain active ingredients

    Low
  • Unknown long-term safety profile

    Moderate
  • Pregnancy and lactation safety unknown

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.